Day: September 19, 2024

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) demonstrated reduction in disease progression, reduced risk of relapse and rapid onset of action VYVGART Hytrulo is first and only neonatal Fc receptor (FcRn) blocker FDA-approved to treat CIDP September 19, 2024 – 7:00 am CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced publication in The Lancet Neurology of the pivotal ADHERE Study, the largest clinical trial to date in chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a rare, debilitating, often progressive, immune-mediated neuromuscular disorder of the peripheral nervous system....

Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household members This is the first time that any antiviral used in the treatment of a respiratory viral illness has demonstrated a transmission reduction benefit in a global phase III study Reducing the spread of infection in the household could help limit transmission within communities and societies, easing the burden of both seasonal and pandemic influenza on healthcare systemsBasel, 19 September – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results of the phase III CENTERSTONE study of Xofluza® (baloxavir marboxil), an antiviral, showing a reduction in the transmission of influenza viruses. The study met its primary endpoint, demonstrating that a single, oral dose of Xofluza taken...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 – Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional half-year and second quarter net results have increased significantly in 2024 compared to 2023 and first quarter 2024 results primarily due to the sale of part of its business to Neurosterix Pharma Sàrl on April 2, 2024. The provisional result amount to a net gain of CHF 9.8 million for the six-month period ended June 30, 2024 compared to a net loss of CHF 5.1 million for the six-month period ended June 30, 2023. The increase of CHF 14.9 million is primarily due to the gross proceeds of CHF 5.0 million received in cash from...

Tonner Drones Convenes GM and Expands Strategy Cannes, 18 September 2024 18:00, Tonner Drones (the “Company”) is pleased to announce that it is convening a shareholders’ general meeting to be held on October 21th (the “GM”) so that shareholders can vote on several important resolutions including the mandate to expand its strategy. Mandate Strategy During the GM, shareholders will be asked to vote on a mandate to implement a new strategy and amend the articles of association accordingly. The Company has successfully completed a restructuring and refinancing process by, among other items, settling various financing contracts and terminating all equity-lines. The Company’s new management is convinced that it can also help other listed companies to escape similar stifling financing structures. The Company is in the position to advise the...

Initial funding of USD 29 million to support development of Basilea’s clinical stage first-in-class antifungals, fosmanogepix and BAL2062 Multi-year Other Transaction Agreement (OTA) allows for potential funding of up to approximately USD 268 million to develop antifungal and antibacterial assets Increasing FY 2024 financial guidance on total revenue, operating result and net profitAd hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 19, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of...

VANCOUVER, British Columbia, Sept. 18, 2024 (GLOBE NEWSWIRE) — Central Iron Ore Limited (CIO – TSX.V) (“CIO” or “the Company”) is pleased to announce this Drilling Update. Central Iron Ore is pleased to announce that the results for the 2024 Phase 1 RC drilling campaign have been finalised.Figure 1. The sun sets after the first day’s drilling of the 2024 Phase 1 RC campaign at British King (M37/30) Highlights:Assay results for the 75-hole, 5 911-meter 2024 Phase 1 RC program has been received and processed. Multiple significant intercepts exceeding has been intercepted across the target area (Table 1) some notable intercepts include;24BKRC_004: 5m @ 20.52g/t from 110 meters 24BKRC_007: 3m @ 28.26g/t from 96 meters 24BKRC_010: 2m @ 24.02g/t from 75 meters 24BKRC_015: 3m @ 35.61g/t from 58 meters 24BKRC_028: 7m @ 8.53g/t...